Last Close
20.49
Jul 23 • 1:20 PM ET Dollar change-0.05 Percentage change(-0.24%)
Index
RUT
Market Cap
685.07M
Enterprise Value
435.68M
Income
-
Sales
-
Book/sh
7.48
Cash/sh
7.51
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
65
IPO
Feb 06, 2026
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
2.74
P/C
2.73
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
38.00
Current Ratio
38.00
Debt/Eq
0.01
LT Debt/Eq
0.01
Option/Short
No / Yes
EPS (ttm)
-
EPS next Y
-2.69
EPS next Q
-0.51
EPS this Y
87.35%
EPS next Y
-18.13%
EPS next 5Y
43.50%
EPS past 3/5Y
-69.04% -
Sales past 3/5Y
- -
EPS Y/Y TTM
-
Sales Y/Y TTM
-
EPS Q/Q
-
Sales Q/Q
-
Insider Own
58.27%
Insider Trans
245.48%
Inst Own
38.29%
Inst Trans
25.11%
ROA
-
ROE
-
ROIC
-
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
0.81%
SMA50
1.75%
SMA200
-11.52%
Trades
Shs Outstand
33.43M
Shs Float
13.95M
52W High
32.44 -36.84%
52W Low
17.06 20.11%
Volatility
7.05% 8.90%
ATR (14)
1.57
RSI (14)
51.64
Beta
-
Rel Volume
0.69
Avg Volume
110.18K
Volume
46,391
Perf Week
-1.30%
Perf Month
4.17%
Perf Quarter
-16.33%
Perf Half Y
-
Perf YTD
-14.62%
Perf Year
-
Perf 3Y
-
Perf 5Y
-
Perf 10Y
-
Prev Close
20.54
Price
20.49
Change
-0.24%
Date Action Analyst Rating Change Price Target Change
Mar-10-26Initiated H.C. Wainwright Buy $37
Mar-03-26Initiated Stifel Buy $42
Mar-03-26Initiated Leerink Partners Outperform $42
Mar-03-26Initiated Jefferies Buy $62
Mar-03-26Initiated Citigroup Buy $42
Jun-15-26 08:00AM
Jun-02-26 08:00AM
May-21-26 08:00AM
May-18-26 08:00AM
May-14-26 04:05PM
04:05PM Loading…
Mar-26-26 04:05PM
Mar-09-26 08:00AM
Mar-04-26 08:00AM
Mar-03-26 09:33AM
08:00AM
Feb-16-26 08:40AM
Feb-09-26 04:05PM
SpyGlass Pharma, Inc. is a late-stage biopharmaceutical, which engages in the development of treatment paradigm for patients living with chronic eye conditions. Its lead product candidate, Bimatoprost Drug Pad-IOL System (BIM-IOL System), is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) for patients who have wither open-angel glaucoma (OAG) or ocular hypertension (OHT). The company was founded in January 2019 by Malik Y. Kahook and Glenn Sussman and is headquartered in Aliso Viejo, CA.
Co-FounderDr. Malik Y. Kahook M.D.
CEO & DirectorMr. Patrick H. Mooney
Chief Research & Development OfficerDr. Chetan Pujara Ph.D.
Co-founder & Chief Technology AdvisorMr. Glenn Sussman
Chief Financial OfficerDr. Jean-Frederic Viret Ph.D.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
RA CAPITAL MANAGEMENT, L.P.DirectorFeb 09 '26Buy16.003,690,00059,040,0005,966,439Feb 11 05:15 PM
Behbahani AliDirectorFeb 09 '26Buy16.00937,50015,000,0006,035,038Feb 11 04:30 PM
Florence Anthony A. Jr.10% OwnerFeb 09 '26Buy16.00937,50015,000,0006,035,038Feb 11 04:30 PM
BASKETT FOREST10% OwnerFeb 09 '26Buy16.00937,50015,000,0006,035,038Feb 11 04:30 PM
New Enterprise Associates 17, 10% OwnerFeb 09 '26Buy16.00937,50015,000,0006,035,038Feb 11 04:30 PM
Yang Rick10% OwnerFeb 09 '26Buy16.00937,50015,000,0006,035,038Feb 11 04:30 PM
Makhzoumi Mohamad10% OwnerFeb 09 '26Buy16.00937,50015,000,0006,035,038Feb 11 04:30 PM
SANDELL SCOTT D10% OwnerFeb 09 '26Buy16.00937,50015,000,0006,035,038Feb 11 04:30 PM
Chang Carmen10% OwnerFeb 09 '26Buy16.00937,50015,000,0006,035,038Feb 11 04:30 PM
Walker Paul Edward10% OwnerFeb 09 '26Buy16.00937,50015,000,0006,035,038Feb 11 04:30 PM
Mathers Edward T10% OwnerFeb 09 '26Buy16.00937,50015,000,0006,035,038Feb 11 04:30 PM
Pardo Geoffrey BDirectorFeb 09 '26Buy16.00312,5005,000,0002,187,513Feb 11 04:09 PM
Khan Bilal ArshadDirectorFeb 09 '26Buy16.00115,0001,840,000251,427Feb 11 04:07 PM
Khan Bilal ArshadDirectorFeb 09 '26Buy16.0020,000320,00025,450Feb 11 04:07 PM
Nielsen Kirk G.DirectorFeb 09 '26Buy16.00165,0002,640,0003,310,619Feb 10 06:09 PM
Vensana Capital I GP, LLC10% OwnerFeb 09 '26Buy16.00165,0002,640,0003,310,619Feb 10 06:08 PM